Novel nanoparticles composed of chitosan and <em>β</em>-cyclodextrin derivatives as potential insoluble drug carrier

doi:10.1016/j.cclet.2015.05.044

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1225 KB) HTML ( )
Export: BibTeX | EndNote (RIS)

Guide Cyclodextrin/chitosan (CD/CS) nanocarriers were successfully prepared with controlled size, spherical morphology and exhibited good stability. This carrier would have a potential application in controlled release of insoluble drugs

Abstract

This research was aim to develop novel cyclodextrin/chitosan (CD/CS) nanocarriers for insoluble drug delivery through themild ionic gelation method previously developed by our lab. A series of different bcyclodextrin (β-CD) derivatives were incorporated into CS nanoparticles including hydroxypropyl-bcyclodextrin (HP-β-CD), sulphobutylether-β-cyclodextrin (SB-β-CD), and 2,6-di-O-methy-β-cyclodextrin (DM-β-CD). Various process parameters for nanoparticle preparation and their effects on physicochemical properties of CD/CS nanoparticles were investigated, such as the type of CD derivatives, CD and CS concentrations, the mass ratio of CS to TPP (CS/TPP), and pH values. In the optimal condition, CD/CS nanoparticles were obtained in the size range of 215-276 nm and with the zeta potential from 30.22 mV to 35.79 mV. Moreover, the stability study showed that the incorporation of CD rendered the CD/CS nanocarriers more stable than CS nanoparticles in PBS buffer at pH 6.8. For their easy preparation and adjustable parameters in nanoparticle formation as well as the diversified hydrophobic core of CD derivatives, the novel CD/CS nanoparticles developed herein might represent an interesting and versatile drug delivery platform for a variety of poorly water-soluble drugs with different physicochemical properties.

Key words： Chitosan Cyclodextrin derivatives Ionic gelation method Drug delivery system

Received: 31 March 2015 Published: 29 May 2015

Fund:

This work was financially supported by Postdoctoral Science Foundation of China (No. 2014M550222), Shanghai Postdoctoral Sustentation Fund (No. 14R21410500). The authors also acknowledge the support from School of Pharmacy, Fudan University & the Open Project Program of Key Lab of Smart Drug Delivery (Fudan University), Ministry of Education (No. SDD2014-2), State Key Laboratory of Molecular Engineering of Polymers (Fudan University, No. K2015-15), and the Fundamental Research Funds for the Central Universities (Nos. 22A201514055 and WY1213013 ECUST).

Corresponding Authors: Feng Gao E-mail: fgao@ecust.edu.cn

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors

Cite this article:

URL:

http://www.chinchemlett.com.cn/EN/10.1016/j.cclet.2015.05.044 OR http://www.chinchemlett.com.cn/EN/Y2015/V26/I07/909

[1]	L. Zhang, F.X. Gu, J.M. Chan, et al., Nanoparticles in medicine: therapeutic applications and developments, Clin. Pharmacol. Ther. 83 (2008) 761-769.
[2]	D. Brambilla, B. Le Droumaguet, J. Nicolas, et al., Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues, Nanomedicine 7 (2011) 521-540.
[3]	A.O. Elzoghby, W.M. Samy, N.A. Elgindy, Albumin-based nanoparticles as potential controlled release drug delivery systems, J. Control. Release 157 (2012) 168-182.
[4]	R. Singh, J.W. Lillard Jr., Nanoparticle-based targeted drug delivery, Exp. Mol. Pathol. 86 (2009) 215-223.
[5]	M. Ferrari, Cancer nanotechnology: opportunities and challenges, Nat. Rev. Cancer 5 (2005) 161-171.
[6]	S. Naahidi, M. Jafari, F. Edalat, K. Raymond, A. Khademhosseini, Biocompatibility of engineered nanoparticles for drug delivery, J. Control. Release 166 (2013) 182-194.
[7]	J.D. Byrne, T. Betancourt, L. Brannon-Peppas, Active targeting schemes for nanoparticle systems in cancer therapeutics, Adv. Drug Del. Rev. 60 (2008) 1615-1626.
[8]	S.A. Agnihotri, N.N. Mallikarjuna, T.M. Aminabhavi, Recent advances on chitosanbasedmicro- andnanoparticles in drug delivery, J. Control. Release 100 (2004) 5-28.
[9]	S.R. Jameela, P.G. Latha, A. Subramoniam, A. Jayakrishnan, Antitumour activity of mitoxantrone-loaded chitosan microspheres against Ehrlich ascites carcinoma, J. Pharm. Pharmacol. 48 (1996) 685-688.
[10]	S. Mitra, U. Gaur, P.C. Ghosh, A.N. Maitra, Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier, J. Control. Release 74 (2001) 317-323.
[11]	P. Yousefpour, F. Atyabi, E. Vasheghani-Farahani, A.A. Movahedi, R. Dinarvand, Targeted delivery of doxorubicin-utilizing chitosan nanoparticles surfacefunctionalized with anti-Her2 trastuzumab, Int. J. Nanomed. 6 (2011) 1977-1990.
[12]	Z.T. Yuan, Y.J. Ye, F. Gao, et al., Chitosan-graft-β-cyclodextrin nanoparticles as a carrier for controlled drug release, Int. J. Pharm. 446 (2013) 191-198.
[13]	S.S. Gao, J. Sun, D.J. Fu, et al., Preparation, characterization and pharmacokinetic studies of tacrolimus-dimethyl-β-cyclodextrin inclusion complex-loaded albumin nanoparticles, Int. J. Pharm. 427 (2012) 410-416.
[14]	Y.J. Ye, Y. Sun, H.L. Zhao, et al., A novel lactoferrin-modified β-cyclodextrinnanocarrier for brain-targeting drug delivery, Int. J. Pharm. 458 (2013) 110-117.
[15]	C. Yang, Recent progress in supramolecular chiral photochemistry, Chin. Chem. Lett. 24 (2013) 437-441.
[16]	H. Hamada, K. Ishihara, N. Masuoka, K. Mikuni, N. Nakajima, Enhancement of water-solubility and bioactivity of paclitaxel using modified cyclodextrins, J. Biosci. Bioeng. 102 (2006) 369-371.
[17]	A. García, D. Leonardi, M.O. Salazar, M.C. Lamas, Modified β-cyclodextrin inclusion complex to improve the physicochemical properties of albendazole. Complete in vitro evaluation and characterization, PLOS ONE 9 (2014) e88234.
[18]	C.A. Ventura, S. Tommasini, A. Falcone, et al., Influence of modified cyclodextrins on solubility and percutaneous absorption of celecoxib through human skin, Int. J. Pharm. 314 (2006) 37-45.
[19]	J.G. Ji, S.L. Hao, W.Q. Liu, et al., Preparation and evaluation of O-carboxymethylchitosan/cyclodextrin nanoparticles as hydrophobic drug delivery carriers, Polym. Bull. 67 (2011) 1201-1213.
[20]	A. Vyas, S. Saraf, S. Saraf, Encapsulation of cyclodextrincomplexed simvastatin in chitosan nanocarriers: a novel technique for oral delivery, J. Incl. Phenom. Macrocycl. Chem. 66 (2010) 251-259.
[21]	A.A. Mahmoud, G.S. El-Feky, R. Kamel, G.E.A. Awad, Chitosan/sulfobutyletherb- cyclodextrin nanoparticles as a potential approach for ocular drug delivery, Int. J. Pharm. 413 (2011) 229-236.
[22]	Y. Yang, Y.M. Zhang, Y. Chen, J.T. Chen, Y. Liu, Targeted polysaccharide nanoparticle for adamplatin prodrug delivery, J. Med. Chem. 56 (2013) 9725-9736.
[23]	D. Zhao, Y. Chen, Y. Liu, Comparative studies on molecular induced aggregation of hepta-imidazoliumyl-β-cyclodextrin towards anionic surfactants, Chin. Chem. Lett. (2014), http://dx.doi.org/10.1016/j.cclet.2014.11.028.
[24]	M.L. Tsai, R.H. Chen, S.W. Bai, W.Y. Chen, The storage stability of chitosan/tripolyphosphate nanoparticles in a phosphate buffer, Carbohydr. Polym. 84 (2011) 756-761.